Core Viewpoint - UBS report indicates that Innovent Biologics is confident in its sales performance in the Chinese market, driven by oncology and cardiovascular products, and aims to achieve a product sales target of 20 billion yuan by 2027 [1] Group 1 - Innovent Biologics is focusing on the sales performance of its products in the Chinese market and the development progress of the key candidate drug IBI363 (PD-1/IL-2a) in collaboration with Takeda Pharmaceutical [1] - The company maintains its target of achieving 20 billion yuan in product sales by 2027 [1] - Innovent aims to advance five candidate drugs into global multi-center randomized controlled trial stages before 2030 [1] Group 2 - UBS sets a target price of HKD 137.4 for Innovent Biologics and maintains a "Buy" rating [1]
大行评级｜瑞银：信达生物维持2027年产品销售额目标 评级“买入”